Chinese Drug Maker Thousand Oaks Biopharmaceuticals Nets $44M In Series A Round

Login to View

Chinese therapeutics medicine developer Thousand Oaks Biopharmaceuticals Co. announced yesterday that they have completed a RMB300 million (US$43.61 million) series A round of financing, led by New Alliance Capital, according to a company statement.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in